Latest Conference Articles

Meredith Cummings BSN, RN, OCN, highlights her research on machine learning and its potential application in optimizing symptom management.

Adjuvant mRNA-4157, in combination with pembrolizumab, improved recurrence-free survival, and distant metastasis-free survival, for patients with high-risk melanoma.

Shivani Gopalsami, RN, MSN, ANP-BC, AOCNP; and Tia Wheatley, DNP, RN, AOCNS, BMTCN, highlight the value of multidisciplinary approaches in hematopoietic stem cell transplantation care.

Phase 2 findings show that adding a tyrosine kinase inhibitor to dual immunotherapy curbed disease progression in patients with metastatic soft tissue sarcoma.

Numerical, but not statistically significant, improvements in survival were observed in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous non–small cell lung cancer who received pembrolizumab to pemetrexed and platinum-based chemotherapy.

Yelena Shames, MSA, ACNP-BC, CNRN, argues that frequent hematologic evaluations may not always be warranted with immune checkpoint inhibitors.

Sintilimab plus chemoradiotherapy was associated with better event-free survival rates in locally advanced nasopharyngeal carcinoma than chemoradiotherapy alone.

A 5-year analysis of the phase 3 KEYNOTE-426 trial showed continued benefit with pembrolizumab plus axitinib for patients with advanced treatment-naïve clear cell renal cell carcinoma.

Axicabtagene ciloleucel delivered superior overall survival compared with standard of care in patients with early relapsed or refractory large B-cell lymphoma.

Patients with pretreated FGFR2/3-altered metastatic urothelial cancer derived a significant survival benefit with erdafitinib.

In the phase 2 DESTINY-PanTumor02 trial, trastuzumab deruxtecan elicited clinical activity across a range of HER2 expressing solid tumors.

Nirogacestat significantly reduced pain scores for patients with desmoid tumors.

Vorasidenib reduced the risk of progression or death by 61% compared with placebo for patients with grade 2 IDH-mutant glioma.

An analysis of patient-reported outcomes in the phase 3 RUBY trial supports dostarlimab use in patients with primary advanced or recurrent endometrial cancer.

Mirvetuximab soravtansine demonstrated an overall survival benefit in FRα-high, platinum-resistant ovarian cancer vs investigator's choice chemotherapy.

Patients with advanced-stage Hodgkin lymphoma who received nivolumab plus AVD experienced a 1-year estimated progression-free survival rate of 94% meeting the primary end point of the phase 3 SWOG S1826 trial.

Preoperative FOLFOX demonstrated noninferior efficacy outcomes vs preoperative chemoradiation in locally advanced rectal cancer.

Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.

Statistically and clinically meaningful improvements in invasive disease-free survival were observed among patients with hormone receptor–positive/HER2-negative early breast cancer who received ribociclib in addition to endocrine therapy.

The 3 year-pelvic recurrence rates with simple hysterectomy were comparable with those of radical hysterectomy among patients with low-risk, early-stage cervical cancer.

Alyssa Ridad BSN-RN, OCN; and Amanda McKaig, BSN, RN, OCN, discuss oncology nurse perceptions of medical cannabis.

Pediatric patients with leukemia in low- and middle-income countries saw improvements in survival outcomes following implementation of the WHO Framework for Action model.

A telephone-based weight loss program proved to be efficacious in overweight or obese women with breast cancer and may lead to improved disease outcomes in the long run.

Over half of patients with lower-risk myelodysplastic syndrome treated with luspatercept achieved transfusion independence.

Patients with pancreatic and gastric cancers residing in states with expanded Medicaid had improved survival rates.

Minimally invasive distal pancreatectomy was a safe and effective alternative compared with open distal pancreatectomy in patients with resectable pancreatic cancer.

Johanna Garibaldi, BSN, RN, EMT-P, discusses how a mobile clinic improved cancer screening rates among local firefighters.

Elizabeth Loach, MSN, APRN, CNS, AGCNS-BC, OCN, highlights how the Oncology Nurse Leader Council at her institution led to frontline nurse task-force engagement.

Seth Eisenberg, ASN, RN, OCN, BMTCN, discusses his research comparing plastic-backed pads and the Splashblocker.

Patricia Jakel, RN, MN, AOCN, underscores some of the challenges nurses face when promoting adherence to oral medications.